Suppr超能文献

慢性淋巴细胞白血病继发多发性骨髓瘤:病例报告及 SEER 数据库数据分析。

Secondary myeloma in patients with chronic lymphoblastic leukemia: A case report and analysis of data from SEER database.

机构信息

Department of Hematology, the First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China.

Department of Nephrology, the First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China.

出版信息

Curr Probl Cancer. 2021 Oct;45(5):100728. doi: 10.1016/j.currproblcancer.2021.100728. Epub 2021 Mar 6.

Abstract

Both chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are common hematological malignancies originating from mature B cells of different differentiation stage. However, it is quite rare that MM could develop after CLL diagnosed. We reported a 66-year-old female progressed forward myeloma 3 years after she was diagnosed as CLL and conducted an analysis to investigate the epidemiology and clinical features among these patients based on the Surveillance, Epidemiology, and End Results (SEER) database. Our data demonstrated that CLL patients were 19% less likely to develop myeloma than general U.S. population (standardized incidence ratio 0.81; 95% confidence interval 0.62-1.03), although without statistical difference. The median overall survival from CLL diagnosed was 90 (58.1-121.9) months, which was the same as general CLL patients according to historical data. But the outcomes of secondary MM was much poorer than general MM patients. Age and gender were independent factors that impact the survival among these patients.

摘要

慢性淋巴细胞白血病(CLL)和多发性骨髓瘤(MM)均为起源于不同分化阶段成熟 B 细胞的常见血液系统恶性肿瘤。然而,CLL 确诊后发展为 MM 较为罕见。我们报道了 1 例 66 岁女性,在确诊 CLL 3 年后进展为骨髓瘤,并基于监测、流行病学和最终结果(SEER)数据库分析了这些患者的流行病学和临床特征。我们的数据表明,CLL 患者发生骨髓瘤的风险比一般美国人群低 19%(标准化发病比 0.81;95%置信区间 0.62-1.03),尽管无统计学差异。从 CLL 确诊到总体生存的中位数为 90(58.1-121.9)个月,与根据历史数据得出的一般 CLL 患者相同。但是,继发性 MM 的预后明显差于一般 MM 患者。年龄和性别是影响这些患者生存的独立因素。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验